Menu

Impact Events

More
Date Lead
Company
Event Type Approval
Change
Approval
Likelihood
12/18/17 Alnylam (ALNY) Patisiran for Transthyretin (TTR)-related Hereditary Amyloidosis (Familial Amyloid Polyneuropathy) Subscribers Only Subscribers Only Subscribers Only
12/18/17 Novartis (NVS) Gilenya for Multiple Sclerosis (MS) Subscribers Only Subscribers Only Subscribers Only
12/15/17 Aclaris (ACRS) Eskata for Benign Pigmented Lesions Subscribers Only Subscribers Only Subscribers Only
12/15/17 Alnylam (ALNY) Fitusiran for Hemophilia A and B - General Clotting Products Subscribers Only Subscribers Only Subscribers Only
12/14/17 Merck (MRK) Keytruda for Gastric Cancer Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected
Date Range
Lead
Company
Drug Expected
Catalyst
12/18/17 Subscribers Only Subscribers Only Regulatory - Supplemental Approval (Europe)
12/18/17 Subscribers Only Subscribers Only Regulatory - Supplemental Approval (Europe)
12/18/17 Subscribers Only Subscribers Only Regulatory - Supplemental Approval (Europe)
12/18/17 Subscribers Only Subscribers Only Regulatory - Supplemental Approval (Europe)
12/18/17 Subscribers Only Subscribers Only Regulatory - Supplemental Approval (Europe)
Back to the top Back to the top